乳腺癌患者血浆纤维蛋白原和D-二聚体及抗凝血酶Ⅲ活性水平的变化及临床意义

Clinical significance of FIB,D-dimer and AT-Ⅲin patients with breast cancer

目的探讨乳腺癌患者血浆纤维蛋白原(FIB)、D-二聚体和抗凝血酶Ⅲ(AT-Ⅲ)活性水平的变化及与临床分期的关系。方法选取川北医学院附属医院2017年7月至2019年1月收治的乳腺癌患者70例(观察组)及同期收治的乳腺良性疾病患者70例(对照组),比较2组患者治疗前血浆FIB、D-二聚体和AT-Ⅲ活性水平,以及不同临床TNM分期、T分期、N分期各指标水平的变化情况。结果观察组血浆FIB、D-二聚体水平均高于对照组[(4.62±0.80)g/L比(3.39±0.73)g/L、(0.59±0.16)mg/L比(0.34±0.13)mg/L],而AT-Ⅲ活性低于对照组[(80±12)%比(96±14)%],差异均有统计学意义(均P<0.05)。乳腺癌患者TNM分期越高,血浆FIB、D-二聚体水平越高,AT-Ⅲ活性越低,差异均有统计学意义(均P<0.05)。乳腺癌患者T分期和N分期越高,血浆FIB水平越高,差异均有统计学意义(均P<0.05);不同T分期和N分期乳腺癌患者血浆D-二聚体、AT-Ⅲ活性水平比较差异均无统计学意义(均P>0.05)。结论乳腺癌患者TNM分期越高,血浆FIB、D-二聚体水平越高,AT-Ⅲ活性越低,监测乳腺癌患者血浆FIB、D-二聚体和AT-Ⅲ活性有助于对患者病情与预后进行评估。

Objective To analyze the plasma fibrinogen(FIB),D-dimer and antithrombinⅢ(AT-Ⅲ)in patients with breast cancer.Methods A total of 70 breast cancer patients(observation group)admitted to the Affiliated Hospital of North Sichuan Medical College from July 2017 to January 2019,and 70 patients with benign breast disease(control group)treated during the same period were analyzed.Plasma FIB,changes of D-dimer and AT-Ⅲactivity levels,and levels of various indicators in different clinical TNM stages,T stages and N stages were analyzed.Results In observation group,plasma FIB,D-dimer level were higher than those in the control group[(4.62±0.80)g/L vs(3.39±0.73)g/L,(0.59±0.16)mg/L vs(0.34±0.13)mg/L];the AT-Ⅲactivity is lower than that in the control group[(80±12)%vs(96±14)%];the differences were all statistically significant(all P<0.05).FIB and D-dimer in patients with high TNM stage was higher,and AT-Ⅲwas lower than those in patients with low TNM stage(P<0.05).Plasma FIB levels in patients with high T and N stages was higher than those in patients with low stages(all P<0.05).Plasma D-dimer and AT-Ⅲactivity levels were not statistically different between breast cancer patients with different T and N stages(P>0.05).Conclusion Breast cancer patients with higher TNM stage have higher plasma FIB,D-dimer levels and lower AT-Ⅲactivity.Monitoring plasma FIB,D-dimer and AT-Ⅲactivity in breast cancer patients can help to assess the patient's condition and prognosis.